April 22, 2015 | The board of directors of Perrigo has rejected the offer made by Mylan NV to purchase its shares $29 billion. Perrigo has reportedly rejected the offer because it feels that it does not reflect the true value of Mylan’s company value and because it does not serve Perrigo’s shareholders’ interests. Simultaneously, Teva Pharmaceutical Industries has offered to purchase Mylan for nearly $41 billion, though Mylan has opposed take-over attempts in the past. Perrigo is the only non-Israeli company listed on the TA-25.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments